Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ARG2 | P78540 | 4/20 | 0.46 |
| ▸ | ARG1 | P05089 | 3/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL3303345 | 1.00 | GSR (0.71) | GSRSMN1; SMN2ARG2ARG1RNPEP | |
| Lysine SCHEMBL27946776 | 0.98 | GSR (0.69) | GSRSMN1; SMN2ARG2ARG1RNPEP | |
| Lysine SCHEMBL11175666 | 0.98 | GSR (0.69) | GSRSMN1; SMN2ARG2ARG1RNPEP | |
| Ornithine SCHEMBL3793499 | 0.95 | GSR (0.62) | GSRSMN1; SMN2ARG2ARG1CYP1A2 | |
| Ornithine SCHEMBL11171112 | 0.93 | GSR (0.60) | GSRSMN1; SMN2ARG2ARG1CYP1A2 | |
| Lysine SCHEMBL2589784 | 0.87 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL31679370 | 0.87 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL1425215 | 0.87 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL20952564 | 0.87 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL18528930 | 0.87 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115569085-A | Supermolecule blue copper peptide solution and preparation method and application thereof | 广州熵增科技有限公司 | 2023-01-06 | — | — | CN | claimed |
| EP-4682242-A1 | SOLUTION FOR SUSPENDING CELLS, AND USE OF SAME | GAIA BioMedicine Inc. (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-20240366673-A1 | METHOD FOR TREATING CELLS | GAIA BIOMEDICINE INC. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-4400576-A1 | METHOD FOR TREATING CELLS | GAIA BioMedicine Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| CN-118103492-A | Method for treating cells | 盖亚生物制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023038037-A1 | METHOD FOR TREATING CELLS | 株式会社ガイアバイオメディシン | 2023-03-16 | — | — | WO | disclosed |
| CN-115569085-A | Supermolecule blue copper peptide solution and preparation method and application thereof | 广州熵增科技有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-115569085-A | Supermolecule blue copper peptide solution and preparation method and application thereof | 广州熵增科技有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-106884029-A | The method of enzyme' s catalysis niacinamide cytimidine dinucleotides | 中国科学院大连化学物理研究所 | 2017-06-23 | — | — | CN | disclosed |
| US-20140323573-A1 | METABOLIZABLE SALTS AND USE THEREOF IN DIAGNOSTICS AND THERAPY | RÜDINGER, Manfred (DE) | 2014-10-30 | — | — | US | disclosed |
| CN-102190589-A | Amino acid ionic liquid for foodstuffs and medical treatments | INST PROCESS ENG CAS | 2011-09-21 | — | — | CN | disclosed |
| EP-2124574-A1 | USE OF TERMITE POWDER INOCULUM FOR IMPROVING CULTURE GROWTH | Institut de Recherche pour le Développement ( IRD) (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008119394-A1 | USE OF TERMITE POWDER INOCULUM FOR IMPROVING CULTURE GROWTH | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (I.R.D.) (FR) | 2008-10-09 | — | — | WO | disclosed |
| CN-1083266-C | Total parenteral nutrition solution containing water-soluble vitamin B | TANABE SEIYAKU CO (JP) | 2002-04-24 | — | — | CN | disclosed |
| EP-0712583-B1 | Total parenteral nutrition solution containing watersoluble vitamin B | TANABE SEIYAKU CO (JP) | 2001-07-18 | — | — | EP | disclosed |
| WO-1998054351-A1 | A COMBINED PROCESS FOR THE PRODUCTION OF LYSINE AND ITS SALTS AND OF A FURTHER WEAK ACID AND A SALT THEREOF | AMYLUM BELGIUM N.V. (BE) | 1998-12-03 | — | — | WO | disclosed |
| US-5767123-A | Total parenteral nutrition solution containing water-soluble vitamin B | TANABE SEIYAKU CO., LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| US-5629002-A | THIOCYANATES IN SYNERGISTIC COMBINATION WITH ESTROGENS, SULFUR, SULFIDES, VASODILATORS, PROTEIN HYDROLYZATES, AMINO ACIDS, CARBOXYLIC ACIDS, VITAMINS | WEUFFEN WOLFGANG (DE) | 1997-05-13 | — | — | US | disclosed |
| CN-1129104-A | Total parenteral nutrition solution containing water-soluble vitamin B | TANABE SEIYAKU CO (JP) | 1996-08-21 | — | — | CN | disclosed |
| EP-0712583-A2 | Total parenteral nutrition solution containing watersoluble vitamin B | TANABE SEIYAKU CO., LTD. (JP) | 1996-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323573-A1 | METABOLIZABLE SALTS AND USE THEREOF IN DIAGNOSTICS AND THERAPY | SLC10A1, BCAT2, BCAT1 | GSR 3116/4885SMN1; SMN2 2479/4885ARG2 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.